关于联合使用纤维蛋白溶解剂/脱氧核糖核酸酶治疗胸腔感染的建议  

Use of fibrinolytics and deoxyribonuclease in patients with pleural infection

作　　者：赵子文[1] 施焕中[2] Zhao Ziwen;Shi Huanzhong(Department of Respiratory and Critical Care Medicine,Guangzhou First People′s Hospital,Guangzhou 510180,China;Department of Respiratory and Critical Care Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing Institute of Respiratory Medicine,Beijing 100020,China)

机构地区：[1]广州市第一人民医院呼吸与危重症医学科,广州510180 [2]首都医科大学附属北京朝阳医院呼吸与危重症医学科,北京呼吸疾病研究所,北京100020

出　　处：《中华医学杂志》2021年第30期2343-2345,共3页National Medical Journal of China

摘　　要：就在十余年前,人们还普遍认为胸腔内注入纤维蛋白溶解剂(纤溶剂)治疗胸腔感染是无效的。随着临床研究证据的逐渐积累,现在国际上已经达成了共识,推荐以胸腔内同时注入纤溶剂和脱氧核糖核酸酶作为胸腔感染的初治用药,或作为外科手术后的后续治疗方案。推荐使用剂量为:组织纤维蛋白溶酶原激活剂10 mg/次,2次/d;脱氧核糖核酸酶5 mg/次,2次/d。建议今后的研究重点将在于摸索出更优化的用药方案,并开发更有效的治疗药物。Just over a decade ago,it was widely accepted that intrapleural instillation of fibrinolytics was ineffective in treatment of pleural infection.Due to the accumulation of clinical study evidence,an expert team from several countries developed an international consensus and recommended that tissue plasminogen activator and deoxyribonuclease should be instilled intrapleurally at the same time as the initial treatment,or as a follow-up treatment after surgery for pleural infection.The recommended dosages are as follows:tissue plasminogen activator 10 mg,twice a day,deoxyribonuclease 5 mg,twice a day.The future researches should focus on optimizing the tissue plasminogen activator and deoxyribonuclease schemes and developing more effective fibrinolytics.

关 键 词：积脓 胸腔 纤溶剂 脱氧核糖核酸酶 

分 类 号：R56[医药卫生—呼吸系统]